source
- Atsena reports early efficacy signals for gene therapy ATSN-201 in X-linked retinoschisis trialAtsena Therapeutics presented data from the early parts of its Lighthouse gene therapy trial for X-linked retinoschisis (XLRS) at the American Academy of Ophthalmology meeting. The trial administe…
- Venture capital continues to flow into biopharma in Q3 2026, favoring later-stage and AI-driven companiesVenture capital funding into biopharma topped $16 billion in the first half of 2026 and kept rising in the third quarter, according to industry sources. Investors remain selective, directing money…